REFERENCES
1. Zeng Q, Oliva VM, Moro MÁ, Scheiermann C. Circadian effects on vascular immunopathologies. Circ Res. 2024;134:791-809.
2. Zhou J, Wang D, Yan B. Infection at the vascular front: a delicate balance between defense and pathology. Microb Pathog. 2026;211:108261.
3. Williams AE, Dunaway LS, Juśkiewicz ZJ, et al. Impact of endothelial diversity and dysfunction on cardiovascular disease. Compr Physiol. 2025;15:e70064.
4. Sudol M. Yes-associated protein (YAP65) is a proline-rich phosphoprotein that binds to the SH3 domain of the Yes proto-oncogene product. Oncogene. 1994;9:2145-52.
5. Kanai F, Marignani PA, Sarbassova D, et al. TAZ: a novel transcriptional co-activator regulated by interactions with 14-3-3 and PDZ domain proteins. EMBO J. 2000;19:6778-91.
6. Reggiani F, Gobbi G, Ciarrocchi A, Sancisi V. YAP and TAZ are not identical twins. Trends Biochem Sci. 2021;46:154-68.
7. Wei Y, Hui VLZ, Chen Y, Han R, Han X, Guo Y. YAP/TAZ: molecular pathway and disease therapy. MedComm. 2023;4:e340.
8. Guo P, Wan S, Guan KL. The Hippo pathway: organ size control and beyond. Pharmacol Rev. 2025;77:100031.
9. Panciera T, Azzolin L, Cordenonsi M, Piccolo S. Mechanobiology of YAP and TAZ in physiology and disease. Nat Rev Mol Cell Biol. 2017;18:758-70.
10. Dupont S, Morsut L, Aragona M, et al. Role of YAP/TAZ in mechanotransduction. Nature. 2011;474:179-83.
12. Yu FX, Zhao B, Panupinthu N, et al. Regulation of the hippo-YAP pathway by G-protein-coupled receptor signaling. Cell. 2012;150:780-91.
13. Suto H. Role of the Hippo-YAP/TAZ Pathway in epithelioid hemangioendothelioma and its potential as a therapeutic target. Anticancer Res. 2024;44:4147-53.
14. Moroishi T, Hansen CG, Guan KL. The emerging roles of YAP and TAZ in cancer. Nat Rev Cancer. 2015;15:73-9.
15. Zhang Z, He P, Yang L, Gong J, Qin R, Wang M. Posttranslational modifications of YAP/TAZ: molecular mechanisms and therapeutic opportunities. Cell Mol Biol Lett. 2025;30:83.
16. Tong T, Huang M, Yan B, et al. Hippo signaling modulation and its biological implications in urological malignancies. Mol Aspects Med. 2024;98:101280.
17. Dong J, Feldmann G, Huang J, et al. Elucidation of a universal size-control mechanism in drosophila and mammals. Cell. 2007;130:1120-33.
18. Piccolo S, Dupont S, Cordenonsi M. The biology of YAP/TAZ: hippo signaling and beyond. Physiol Rev. 2014;94:1287-312.
19. Fu M, Hu Y, Lan T, Guan KL, Luo T, Luo M. The Hippo signalling pathway and its implications in human health and diseases. Signal Transduct Target Ther. 2022;7:376.
20. Di X, Gao X, Peng L, et al. Cellular mechanotransduction in health and diseases: from molecular mechanism to therapeutic targets. Signal Transduct Target Ther. 2023;8:282.
21. Daoud F, Arévalo Martinez M, Holmberg J, et al. YAP and TAZ in vascular smooth muscle confer protection against hypertensive vasculopathy. Arterioscler Thromb Vasc Biol. 2022;42:428-43.
22. Yamashiro Y, Thang BQ, Ramirez K, et al. Matrix mechanotransduction mediated by thrombospondin-1/integrin/YAP in the vascular remodeling. Proc Natl Acad Sci U S A. 2020;117:9896-905.
23. Ritsvall O, Albinsson S. Emerging role of YAP/TAZ in vascular mechanotransduction and disease. Microcirculation. 2024;31:e12838.
24. Mannion AJ, Zhao H, Zhang Y, et al. Regulation of YAP promotor accessibility in endothelial mechanotransduction. Arterioscler Thromb Vasc Biol. 2024;44:666-89.
25. Wang Y, Chatterjee E, Li G, Xu J, Xiao J. Force-sensing protein expression in response to cardiovascular mechanotransduction. EBioMedicine. 2024;110:105412.
26. Seetharaman S, Vianay B, Roca V, et al. Microtubules tune mechanosensitive cell responses. Nat Mater. 2022;21:366-77.
27. Holland EN, Fernández-Yagüe MA, Zhou DW, et al. FAK, vinculin, and talin control mechanosensitive YAP nuclear localization. Biomaterials. 2024;308:122542.
28. Liu X, Yuan Y, Wu Y, Zhu C, Liu Y, Ke B. Extracellular matrix stiffness modulates myopia scleral remodeling through integrin/F-Actin/YAP axis. Invest Ophthalmol Vis Sci. 2025;66:22.
29. Mehta V, Tzima E. Cardiovascular disease: a turbulent path to plaque formation. Nature. 2016;540:531-2.
30. Fang Y, Wu D, Birukov KG. Mechanosensing and mechanoregulation of endothelial cell functions. Compr Physiol. 2019;9:873-904.
31. Wang KC, Yeh YT, Nguyen P, et al. Flow-dependent YAP/TAZ activities regulate endothelial phenotypes and atherosclerosis. Proc Natl Acad Sci U S A. 2016;113:11525-30.
32. Liu J, Zhao C, Xiao X, et al. Endothelial discoidin domain receptor 1 senses flow to modulate YAP activation. Nat Commun. 2023;14:6457.
33. Jiang M, Ding H, Huang Y, et al. Endothelial serotonin receptor 1b acts as a mechanosensor to drive atherosclerosis. Circ Res. 2025;136:887-901.
34. Jiang MC, Ding HY, Cheng CK, et al. Targeting the 5-HT(1B)-YAP positive feedback loop protects against disturbed flow-induced atherogenesis in mice. Acta Pharmacol Sin. 2026;47:666-76.
35. Jetta D, Gottlieb PA, Verma D, Sachs F, Hua SZ. Shear stress-induced nuclear shrinkage through activation of Piezo1 channels in epithelial cells. J Cell Sci. 2019;132:jcs226076.
36. Oliva MAG, Ciccone G, Fläschner G, et al. Piezo1 regulates the mechanotransduction of soft matrix viscoelasticity. Nat Commun. 2025;16:9155.
37. Li B, He J, Lv H, et al. c-Abl regulates YAPY357 phosphorylation to activate endothelial atherogenic responses to disturbed flow. J Clin Invest. 2019;129:1167-79.
38. Narayanasamy A, Karuppusamy PA, Gnanarajan R, et al. Mechanobiology-driven metabolic reprogramming: integrative roles of YAP/TAZ signaling and extracellular matrix dynamics. Cell Biol Int. 2026;50:e70180.
39. Tian G, Ren T. Mechanical stress regulates the mechanotransduction and metabolism of cardiac fibroblasts in fibrotic cardiac diseases. Eur J Cell Biol. 2023;102:151288.
40. Lei Y, Liu Q, Chen B, et al. Protein O-GlcNAcylation coupled to Hippo signaling drives vascular dysfunction in diabetic retinopathy. Nat Commun. 2024;15:9334.
41. Chen X, Wang H, Wu C, et al. Endothelial H2S-AMPK dysfunction upregulates the angiocrine factor PAI-1 and contributes to lung fibrosis. Redox Biol. 2024;70:103038.
42. Liu Y, Li M, Lv X, et al. Yes-Associated protein targets the transforming growth factor β pathway to mediate high-fat/high-sucrose diet-induced arterial stiffness. Circ Res. 2022;130:851-67.
43. Liu Y, Li M, Chen Z, et al. BRISC-mediated PPM1B-K63 deubiquitination and subsequent TGF-β pathway activation promote high-fat/high-sucrose diet-induced arterial stiffness. Circ Res. 2025;136:297-314.
44. Ong YT, Andrade J, Armbruster M, et al. A YAP/TAZ-TEAD signalling module links endothelial nutrient acquisition to angiogenic growth. Nat Metab. 2022;4:672-82.
45. Deng Q, Ji Y, Liu J, Wen T. Lipid reprogramming and ferroptosis crosstalk in clear cell renal cell carcinoma: metabolic vulnerabilities and therapeutic targeting. Mol Cancer. 2025;24:236.
46. Sorrentino G, Ruggeri N, Specchia V, et al. Metabolic control of YAP and TAZ by the mevalonate pathway. Nat Cell Biol. 2014;16:357-66.
47. Yousfi Y, Mora-Molina R, López-Rivas A, Yerbes R. Role of the YAP/TAZ-TEAD transcriptional complex in the metabolic control of TRAIL sensitivity by the mevalonate pathway in cancer cells. Cells. 2023;12:2370.
48. Rachedi NS, Tang Y, Tai YY, et al. Dietary intake and glutamine-serine metabolism control pathologic vascular stiffness. Cell Metab. 2024;36:1335-1350.e8.
49. Bertero T, Oldham WM, Cottrill KA, et al. Vascular stiffness mechanoactivates YAP/TAZ-dependent glutaminolysis to drive pulmonary hypertension. J Clin Invest. 2016;126:3313-35.
50. Bai J, Yang Y. Activation of Hippo/YAP signaling pathway exacerbates vascular remodeling and aggravates hypertension by upregulating Foxm1. J Mol Histol. 2025;56:158.
51. Zhou Y, Yang Y, Wang Y, Cheang WS. Targeting endoplasmic reticulum stress and YAP/TAZ-SMAD1/5 signaling to ameliorate endothelial dysfunction in diabetes. Acta Pharmacol Sin. 2026.
52. Veerasubramanian PK, Meli VS, Atcha H, Wang W, Downing TL, Liu WF. BET inhibition curbs macrophage inflammation, lipid accumulation, and atherogenesis by disrupting the YAP/TAZ-BRD4 axis. J Leukoc Biol. 2026:118.
53. Kobayashi S, Cox AG, Harvey KF, Hogan BM. Vasculature is getting Hip(po): Hippo signaling in vascular development and disease. Dev Cell. 2023;58:2627-40.
54. Li R, Shao J, Jin YJ, et al. Endothelial FAT1 inhibits angiogenesis by controlling YAP/TAZ protein degradation via E3 ligase MIB2. Nat Commun. 2023;14:1980.
55. Hooglugt A, van der Stoel MM, Shapeti A, et al. DLC1 promotes mechanotransductive feedback for YAP via RhoGAP-mediated focal adhesion turnover. J Cell Sci. 2024:137.
56. Neyazi B, Swiatek VM, Karimpour MA, et al. The role of Hippo signaling in brain arteriovenous malformations: molecular insights into post-embolization remodeling. Int J Mol Sci. 2025;26:3791.
57. Zhang M, Jiang WI, Arkelius K, Swanson RA, Ma DK, Singhal NS. PATJ regulates cell stress responses and vascular remodeling post-stroke. Redox Biol. 2025;85:103709.
58. Savorani C, Malinverno M, Seccia R, et al. A dual role of YAP in driving TGFβ-mediated endothelial-to-mesenchymal transition. J Cell Sci. 2021:134.
59. Jia M, Li Q, Guo J, et al. Deletion of BACH1 attenuates atherosclerosis by reducing endothelial inflammation. Circ Res. 2022;130:1038-55.
60. Chao ML, Luo S, Zhang C, et al. S-nitrosylation-mediated coupling of G-protein alpha-2 with CXCR5 induces Hippo/YAP-dependent diabetes-accelerated atherosclerosis. Nat Commun. 2021;12:4452.
61. Barettino A, González-Gómez C, Gonzalo P, et al. Endothelial YAP/TAZ activation promotes atherosclerosis in a mouse model of Hutchinson-Gilford progeria syndrome. J Clin Invest. 2024:134.
62. Medrano-Bosch M, Simón-Codina B, Jiménez W, Edelman ER, Melgar-Lesmes P. Monocyte-endothelial cell interactions in vascular and tissue remodeling. Front Immunol. 2023;14:1196033.
63. Shen Y, Goncharov DA, Pena A, et al. Cross-talk between TSC2 and the extracellular matrix controls pulmonary vascular proliferation and pulmonary hypertension. Sci Signal. 2022;15:eabn2743.
64. Keshavarz M, Smith Q. Gelatin-mediated vascular self-assembly via a YAP-MMP signaling axis. Adv Funct Mater. 2024;34:2402360.
65. Wang L, Chennupati R, Jin YJ, et al. YAP/TAZ are required to suppress osteogenic differentiation of vascular smooth muscle cells. iScience. 2020;23:101860.
66. Albinsson S, Rippe C, Daoud F, et al. Hippo in smooth muscle - a therapeutic target in vascular diseases driven by aging and hypertension. Front Physiol. 2025;16:1674714.
67. Arévalo Martínez M, Ritsvall O, Bastrup JA, et al. Vascular smooth muscle-specific YAP/TAZ deletion triggers aneurysm development in mouse aorta. JCI Insight. 2023;8:e170845.
68. Sladitschek-Martens HL, Guarnieri A, Brumana G, et al. YAP/TAZ activity in stromal cells prevents ageing by controlling cGAS-STING. Nature. 2022;607:790-8.
69. Yu Q, Li W, Jin R, et al. PI3Kγ (phosphoinositide 3-kinase γ) regulates vascular smooth muscle cell phenotypic modulation and neointimal formation through CREB (cyclic AMP-response element binding protein)/YAP (yes-associated protein) signaling. Arterioscler Thromb Vasc Biol. 2019;39:e91-e105.
70. Garoffolo G, Sluiter TJ, Thomas A, et al. Blockade of YAP mechanoactivation prevents neointima formation and adverse remodeling in arterialized vein grafts. J Am Heart Assoc. 2025;14:e037531.
71. Zhang FR, Tang J, Lai Y, et al. Smooth muscle cell Piezo1 is essential for phenotypic switch and neointimal hyperplasia. Br J Pharmacol. 2025;182:2031-48.
72. Shao J, Kwon J, Wang T, et al. Orphan receptor GPR153 facilitates vascular damage responses by modulating cAMP levels, YAP/TAZ signaling, and NF-κB activation. Nat Commun. 2025;16:6232.
73. Li Y, Chen X, Xu X, et al. OTUB2 contributes to vascular calcification in chronic kidney disease via the YAP-mediated transcription of PFKFB3. Theranostics. 2025;15:1185-204.
74. Kudryashova TV, Goncharov DA, Pena A, et al. HIPPO-integrin-linked kinase cross-talk controls self-sustaining proliferation and survival in pulmonary hypertension. Am J Respir Crit Care Med. 2016;194:866-77.
75. Yang H, Zhong Y, Guo W, et al. TAX1BP3 is a SUMOylated nucleocytoplasmic shuttling protein and protects against vascular neointimal hyperplasia. Circulation. 2025;152:1087-108.
78. Ye C, Zheng F, Xu T, et al. Norepinephrine acting on adventitial fibroblasts stimulates vascular smooth muscle cell proliferation via promoting small extracellular vesicle release. Theranostics. 2022;12:4718-33.
79. Xie C, Hu Y, Yin Z. Inhibiting YAP1 reduced abdominal aortic aneurysm formation by suppressing adventitial fibroblast phenotype transformation and migration. J Cell Mol Med. 2024;28:e70159.
80. Pan X, Zhang R, Lu B, et al. SM22α-lineage perivascular stromal cells contribute to abdominal aortic aneurysm. Circ Res. 2025;137:4-22.
81. Liang N, Zhang C, Dill P, et al. Regulation of YAP by mTOR and autophagy reveals a therapeutic target of tuberous sclerosis complex. J Exp Med. 2014;211:2249-63.
82. Collins JM, Lang A, Parisi C, et al. YAP and TAZ couple osteoblast precursor mobilization to angiogenesis and mechanoregulation in murine bone development. Dev Cell. 2024;59:211-227.e5.
83. Shi H, Liang W, Yang Z, et al. Microvascular endothelial cells license APS vasculopathy through YAP1- and CCN2-mediated signaling. Circulation. 2025;152:1295-310.
84. Ren Z, Xu Z, Chang X, Liu J, Xiao W. STC1 competitively binding βPIX enhances melanoma progression via YAP nuclear translocation and M2 macrophage recruitment through the YAP/CCL2/VEGFA/AKT feedback loop. Pharmacol Res. 2024;204:107218.
85. Wei Q, Du F, Cui J, et al. Non-monotonic response of macrophages to mechanical stretch impacts skin wound healing. Cell Mol Biol Lett. 2025;30:82.
86. Mia MM, Ghani SABA, Cibi DM, et al. YAP/TAZ are crucial regulators of macrophage-mediated pulmonary inflammation and fibrosis after bleomycin-induced injury. Eur Respir J. 2025;65:2301544.
87. Huang LS, Hong Z, Wu W, et al. mtDNA activates cGAS signaling and suppresses the YAP-mediated endothelial cell proliferation program to promote inflammatory injury. Immunity. 2020;52:475-486.e5.
88. Mia MM, Cibi DM, Abdul Ghani SAB, et al. YAP/TAZ deficiency reprograms macrophage phenotype and improves infarct healing and cardiac function after myocardial infarction. PLoS Biol. 2020;18:e3000941.
89. Huang HC, Wang TY, Rousseau J, et al. Biomimetic nanodrug targets inflammation and suppresses YAP/TAZ to ameliorate atherosclerosis. Biomaterials. 2024;306:122505.
90. Shi Y, Xu Z, Wang H, et al. Scaffolding protein ENH promotes tumor angiogenesis and growth through macrophage recruitment and polarization. Adv Sci. 2025;12:e16476.
91. Chen L, Jin X, Ma J, Xiang B, Li X. YAP at the progression of inflammation. Front Cell Dev Biol. 2023;11:1204033.
92. Choi HJ, Kim NE, Kim BM, Seo M, Heo JH. TNF-α-induced YAP/TAZ activity mediates leukocyte-endothelial adhesion by regulating VCAM1 expression in endothelial cells. Int J Mol Sci. 2018;19:3428.
93. Lv Y, Kim K, Sheng Y, et al. YAP controls endothelial activation and vascular inflammation through TRAF6. Circ Res. 2018;123:43-56.
94. Zhang F, Cusick JK, Liang J, et al. YAP promotes microtubule growth to facilitate sarcomere disassembly in adult cardiomyocytes. Circulation. 2026;154:934-55.
95. Symons RA, Colella F, Collins FL, et al. Targeting the IL-6-Yap-Snail signalling axis in synovial fibroblasts ameliorates inflammatory arthritis. Ann Rheum Dis. 2022;81:214-24.
96. Wrighton KH. Metabolism: YAP and TAZ under metabolic control. Nat Rev Mol Cell Biol. 2014;15:296.
97. Benhammou JN, Qiao B, Ko A, Sinnett-Smith J, Pisegna JR, Rozengurt E. Lipophilic statins inhibit YAP coactivator transcriptional activity in HCC cells through Rho-mediated modulation of actin cytoskeleton. Am J Physiol Gastrointest Liver Physiol. 2023;325:G239-50.
98. Liu C, Shen M, Tan WLW, et al. Statins improve endothelial function via suppression of epigenetic-driven EndMT. Nat Cardiovasc Res. 2023;2:467-85.
99. Wang L, Luo JY, Li B, et al. Integrin-YAP/TAZ-JNK cascade mediates atheroprotective effect of unidirectional shear flow. Nature. 2016;540:579-82.
100. Wang C, Zhu X, Feng W, et al. Verteporfin inhibits YAP function through up-regulating 14-3-3σ sequestering YAP in the cytoplasm. Am J Cancer Res. 2016;6:27-37.
101. Graham K, Lienau P, Bader B, et al. Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signaling. Cell Chem Biol. 2024;31:1247-1263.e16.
102. Hagenbeek TJ, Zbieg JR, Hafner M, et al. An allosteric pan-TEAD inhibitor blocks oncogenic YAP/TAZ signaling and overcomes KRAS G12C inhibitor resistance. Nat Cancer. 2023;4:812-28.
103. Yap TA, Kwiatkowski DJ, Dagogo-Jack I, et al. YAP/TEAD inhibitor VT3989 in solid tumors: a phase 1/2 trial. Nat Med. 2025;31:4281-90.
104. Zhou R, Wang H, Zhang GM, et al. Targeted degradation of endogenous YAP by nanobody bioPROTAC inhibits tumor progression. Nat Commun. 2025;16:9374.
105. Harvey KF, Tang TT. Targeting the Hippo pathway in cancer. Nat Rev Drug Discov. 2025;24:852-69.
106. Liu-Chittenden Y, Huang B, Shim JS, et al. Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. Genes Dev. 2012;26:1300-5.
